NASDAQ I think reports in August not quarterly. I was just thinking about the SCLC data a bit more.
According to corporate presentation, they completed enrollment on 9/6/2016 and we got a PR on 9/7. Now, most of these patients don't live very long due to the cancer. From beginning of September until July, it's well over 10 months now approaching 11 month by August 6.
Topotecan outcomes PFS 3 months, OS 7-8 months ok. So if SCLC has not been concluded yet, it means the result is probably better and OS potentially greater than 7-8 months. Assuming OS is about the same which was expected and PFS being the end point, and it takes the trial center 30 days to deliver the result. Cytrx should already have the data on hand.
Assuming 8 months OS, trial should have ended early May and data is probably available for to Cytrx early June. This is why IR keeps saying Q2 release.
Ok, so it's July 21 today. That can mean two things. OS ended up greater than 8 months. If that was the case it's excellent results that will make this fly in due time. But, if what SK said was true during the shareholders meeting cytrx is under a none disclosure agreement. It only means they have a deal lined up. Either way, this is good sign.
Now, SK have no reason to hold that result back if they don't have a suitor yet. He would have released that data to attract higher bidder. The fact that this is confidential means multiple bidders and Cytrx probably have a confidential disclosure agreement in place.
But we don't know how long negotiation will take and the delisting threat is hanging there, the stock still have major risk that's preventing it from running anywhere soon.
But what the above said, I think I am willing to risk a bit more here.
